Thrombolytic therapy and acute myocardial infarction

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Acute myocardial infarction (AMI) is characterized by coronary thrombosis and subsequent cardiac muscle necrosis.
• Intravenous thrombolytic therapy is a cornerstone in managing AMI, aiming to dissolve clots and restore blood flow.
• The efficacy of thrombolytic agents is influenced by factors like generation and combination with antiplatelet drugs.

Purpose of the Study:

• To review the role of intravenous thrombolytic therapy in acute myocardial infarction.
• To compare the effectiveness of different generations of thrombolytic agents.
• To evaluate the impact of acetylsalicylic acid on thrombolysis and mortality in AMI patients.

Main Methods:

• Review of existing clinical data and studies on thrombolytic therapy for AMI.
• Analysis of mortality reduction and myocardial salvage associated with different treatment strategies.
• Assessment of the time-dependency of thrombolytic therapy effectiveness.

Main Results:

• Intravenous thrombolytic therapy significantly reduces mortality and preserves left ventricular function in AMI.
• Second-generation thrombolytics like APSAC and rt-PA may offer superior efficacy compared to streptokinase.
• Additive therapy with low-dose acetylsalicylic acid enhances thrombolysis and improves survival rates.

Conclusions:

• Early administration of intravenous thrombolytic therapy is critical in managing acute myocardial infarction.
• The choice of thrombolytic agent and the concurrent use of acetylsalicylic acid can optimize treatment outcomes.
• Treatment timing is paramount, emphasizing the 'race against time' in AMI management.